首页> 美国卫生研究院文献>International Journal of Molecular Sciences >A Novel Synthetic Compound (E)-5-((4-oxo-4H-chromen-3-yl)methyleneamino)-1-phenyl-1H-pyrazole-4-carbonitrile Inhibits TNFα-Induced MMP9 Expression via EGR-1 Downregulation in MDA-MB-231 Human Breast Cancer Cells
【2h】

A Novel Synthetic Compound (E)-5-((4-oxo-4H-chromen-3-yl)methyleneamino)-1-phenyl-1H-pyrazole-4-carbonitrile Inhibits TNFα-Induced MMP9 Expression via EGR-1 Downregulation in MDA-MB-231 Human Breast Cancer Cells

机译:一种新的合成化合物(E)-5 - ((4-氧代-4H- Chromen-3-Y1)甲基氨基)-1-苯基-1H-吡唑-4-腈抑制TNFα诱导的MMP9表达通过EGR-1下调MDA-MB-231人乳腺癌细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer is a common malignancy among women worldwide. Gelatinases such as matrix metallopeptidase 2 (MMP2) and MMP9 play crucial roles in cancer cell migration, invasion, and metastasis. To develop a novel platform compound, we synthesized a flavonoid derivative, (E)-5-((4-oxo-4H-chromen-3-yl)methyleneamino)-1-phenyl-1H-pyrazole-4-carbonitrile (named DK4023) and characterized its inhibitory effects on the motility and and expression of highly metastatic MDA-MB-231 breast cancer cells. We found that DK4023 inhibited tumor necrosis factor alpha (TNFα)-induced motility and F-actin formation of MDA-MB-231 cells. DK4023 also suppressed the TNFα-induced mRNA expression of through the downregulation of the TNFα-extracellular signal-regulated kinase (ERK)/early growth response 1 (EGR-1) signaling axis. These results suggest that DK4023 could serve as a potential platform compound for the development of novel chemopreventive/chemotherapeutic agents against invasive breast cancer.
机译:乳腺癌是全世界妇女的常见恶性肿瘤。凝胶酶如基质金属肽酶2(MMP2)和MMP9在癌细胞迁移,侵袭和转移中起重要作用。开发一种新型平台化合物,我们合成了一种类黄酮衍生物,(E)-5 - ((4-氧代-4H-铬-3-基)甲基氨基)-1-苯基-1H-吡唑-4-甲腈(名为DK4023 )其对高度转移性MDA-MB-231乳腺癌细胞的运动和表达的表征其抑制作用。我们发现DK4023抑制肿瘤坏死因子α(TNFα)诱导的MDA-MB-231细胞的运动和F-肌动蛋白形成。 DK4023还抑制了通过TNFα - 细胞信号调节激酶(ERK)/早期生长响应1(EGR-1)信号轴的下调的TNFα诱导的mRNA表达。这些结果表明DK4023可以作为潜在平台化合物,用于开发用于侵入乳腺癌的新型化学预防/化学治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号